Skip to Content

Pfizer to pay $2.26B for cancer treatment developer Trillium

KVIA

By The Associated Press

Pfizer is spending more than $2 billion in cash to buy another drugmaker focused on potential cancer treatments. New York-based Pfizer says it will pay $18.50 for each share of Trillium Therapeutics Inc., or more than double the stock’s 60-day weighted average price. Trillium has no products on the market. Its potential treatments include biologics that aim to prime a patient’s immune system to detect and destroy cancer cells. Its two lead candidates are in early-stage testing and focus on hematology. That includes blood, bone marrow and lymph node cancers like leukemia or lymphoma.

Article Topic Follows: AP National Business

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

KVIA ABC 7 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content